Prestige Consumer Healthcare Inc.: insider trades · United States · SEC (Form 4)

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a United States consumer healthcare company focused on over-the-counter (OTC) health and personal care products. The company was incorporated in Delaware in 1996 and has built its business around established, name-brand consumer franchises rather than around large-scale prescription pharmaceuticals. Its principal executive offices are in Tarrytown, New York, United States. For French, Belgian and Swiss investors, PBH is best viewed as a branded consumer-health platform with a defensive profile, recurring demand characteristics and strong cash-generation potential. Through its wholly owned subsidiaries, Prestige develops, manufactures, markets, sells and distributes a broad portfolio of OTC products across several everyday health categories. Its core brand family includes well-known names such as Dramamine, Fleet, Clear Eyes, Monistat, Nix, Chloraseptic, Debrox, TheraTears, DenTek, Goody’s, BC, Summer’s Eve, Boudreaux’s Butt Paste and Hydralyte. The company’s products address gastrointestinal health, eye care, oral care, skin care, cough and cold, and women’s health, giving it a diversified but still focused portfolio in consumer self-care. Prestige’s commercial footprint is concentrated in North America, where it sells into mass merchandisers, drugstores, food retailers, dollar stores, convenience channels, club stores and e-commerce. The group also has exposure to Australia and certain other international markets. Its competitive position is built on brand equity, distribution breadth, a low-cost operating model and disciplined marketing execution. In practical terms, Prestige competes not as a diversified pharma giant, but as a specialist owner of mature, trusted OTC brands with strong shelf presence and consumer recognition. Recent developments reinforce that strategy. In fiscal 2025 and fiscal 2026, management highlighted record or near-record financial performance, strong free cash flow and ongoing share repurchases. The company also continued a targeted M&A strategy: it completed the acquisition of Pillar5 Pharma in December 2025, expanding its eye-care capabilities, and in May 2026 announced an agreement to acquire LaCorium Health, an Australian therapeutic skin-care leader. Management also noted operational headwinds such as limited supply for Clear Eyes and some shipping disruptions in the Middle East, but overall described the business model as resilient in a difficult consumer environment. As a result, PBH remains a NYSE-listed United States company with a portfolio-driven model, modest geographic diversification, and a strategy centered on brand stewardship, selective acquisitions, and capital allocation discipline.